JAKAFI
Drug
Incyte Corporation
Total Payments
$19.2M
Transactions
82,198
Doctors
14,153
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.2M | 14,938 | 6,016 |
| 2023 | $2.6M | 15,620 | 5,785 |
| 2022 | $2.4M | 10,539 | 4,151 |
| 2021 | $2.2M | 9,086 | 3,518 |
| 2020 | $1.6M | 5,290 | 2,185 |
| 2019 | $2.5M | 9,620 | 3,303 |
| 2018 | $2.6M | 7,547 | 2,673 |
| 2017 | $3.1M | 9,558 | 3,136 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12.6M | 4,444 | 65.6% |
| Travel and Lodging | $2.2M | 7,475 | 11.5% |
| Food and Beverage | $1.8M | 69,088 | 9.3% |
| Consulting Fee | $1.7M | 459 | 9.1% |
| Space rental or facility fees (teaching hospital only) | $793,675 | 477 | 4.1% |
| Unspecified | $49,308 | 18 | 0.3% |
| Education | $4,415 | 237 | 0.0% |
Payments by Type
General
$19.2M
82,180 transactions
Research
$49,308
18 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI NATIONAL OPEN LABEL PHASE II STUDY OF THE JAKINHIBITOR INC424 IN PATIENTS WITH PRIMARY MYELOFIBROSISPOST POLYCYTHEMIA VERA MYELOFIBROSIS OR POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS | Novartis Pharmaceuticals Corporation | $28,125 | 0 |
| A MULTI NATIONAL OPEN LABEL PHASE II STUDY OF THE JAKINHIBITOR INC424 IN PATIENTS WITH PRIMARY MYELOFIBROSISPOST POLYCYTHEMIA VERA MYELOFIBROSIS OR POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS | NOVARTIS PHARMACEUTICALS CORPORATION | $16,125 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,153 | 1 |
| A PHASE IB OPEN LABEL MULTI CENTER TWO ARM DOSE FINDINGSTUDY TO ASSESS THE SAFETY AND EFFICACY OF THE ORALCOMBINATION OF RUXOLITINIB INC424 AND BKM120 INPATIENTS WITH PRIMARY MYELOFIBROSIS PMF POSTPOLYCYTHEMIAVERA MYELOFIBROSIS PPVMF OR POSTESSENTIALTHROMBOCYTHEMIA MYELOFIBROSIS PETMF | Novartis Pharmaceuticals Corporation | $1,125 | 0 |
| RUXOLITINIB VERSUS STANDARD THERAPY AS INITIAL TREATMENT IN HIGH RISK PV AND HIGH RISK ET | Novartis Pharmaceuticals Corporation | $1,125 | 1 |
| A PHASE IB OPEN LABEL DOSE FINDING STUDY OF THE JAK INHIBITOR INC424 TABLETS ADMINISTERED ORALLY TO PATIENTS WITH PRIMARY MYELOFIBROSIS PMF POST POLYCYTHEMIA VERA MYELOFIBROSIS PPVMF OR POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS PETMF AND BASELINE PLATE | Novartis Pharmaceuticals Corporation | $505.00 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $150.00 | 1 |
Top Doctors Receiving Payments for JAKAFI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Iowa City, IA | $825,750 | 527 |
| , MD | Hematology & Oncology | New Orleans, LA | $690,893 | 713 |
| , MD | Medical Oncology | Chandler, AZ | $605,742 | 924 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $570,368 | 586 |
| , M.D | Hematology & Oncology | Morristown, NJ | $548,571 | 660 |
| , MD | Medical Oncology | Dallas, TX | $484,344 | 492 |
| , MD | Hematology | Sioux Falls, SD | $483,240 | 396 |
| , MD | Internal Medicine | Ann Arbor, MI | $465,496 | 341 |
| , MD | Hematology & Oncology | New York, NY | $416,880 | 458 |
| , M.D | Internal Medicine | Omaha, NE | $395,530 | 355 |
| , MD | Hematology & Oncology | Huntington, WV | $336,190 | 429 |
| , M.D | Hematology & Oncology | Sioux Falls, SD | $316,321 | 285 |
| , M.D | Hematology & Oncology | Ft Lauderdale, FL | $312,861 | 299 |
| , MD | Medical Oncology | Boston, MA | $271,344 | 197 |
| , M.D | Medical Oncology | Durham, NC | $264,608 | 178 |
| Bart Scott | Medical Oncology | Seattle, WA | $251,264 | 213 |
| , APN | Nurse Practitioner | Las Vegas, NV | $249,265 | 499 |
| , M.D | Hematology | Hawthorne, NY | $246,351 | 170 |
| , MD | Internal Medicine | Las Vegas, NV | $227,634 | 226 |
| , MD | Hematology & Oncology | Gilbert, AZ | $226,889 | 278 |
| , MD | Hematology & Oncology | Orlando, FL | $226,465 | 225 |
| , MD | Student in an Organized Health Care Education/Training Program | Westwood, KS | $205,046 | 162 |
| , M.D | Hematology & Oncology | Tucson, AZ | $204,193 | 177 |
| , M.D | Hematology & Oncology | Elk Grove Village, IL | $200,716 | 201 |
| , D.O | Internal Medicine | Oak Brook, IL | $196,877 | 215 |
Ad
Manufacturing Companies
- Incyte Corporation $19.1M
- Novartis Pharmaceuticals Corporation $78,953
- Novartis Pharma AG $44,614
- NOVARTIS PHARMACEUTICALS CORPORATION $18,278
Product Information
- Type Drug
- Total Payments $19.2M
- Total Doctors 14,153
- Transactions 82,198
About JAKAFI
JAKAFI is a drug associated with $19.2M in payments to 14,153 healthcare providers, recorded across 82,198 transactions in the CMS Open Payments database. The primary manufacturer is Incyte Corporation.
Payment data is available from 2017 to 2024. In 2024, $2.2M was paid across 14,938 transactions to 6,016 doctors.
The most common payment nature for JAKAFI is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($12.6M, 65.6% of total).
JAKAFI is associated with 7 research studies, including "A MULTI NATIONAL OPEN LABEL PHASE II STUDY OF THE JAKINHIBITOR INC424 IN PATIENTS WITH PRIMARY MYELOFIBROSISPOST POLYCYTHEMIA VERA MYELOFIBROSIS OR POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS" ($28,125).